|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||33.60 / 50.40|
The settlement provides Mylan with global licenses for its trastuzumab product.
A firestorm in Washington has created a fire sale for shares of this undervalued stock.
Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.
Jim Cramer ponders the bull market and whether the drug rally is 'Trumped up.'
The scandals plaguing the pharmaceutical company can be traced to lack of change at the board level.
Is this small-cap biotech play the best way to profit from the growing worldwide demand for vaccines?
Forty states have now sued the companies.
Stocks enjoy their best gains of the year as investors rejoice over the Federal Reserve's apparent faith in the U.S. economy.
Stocks hold big gains through Wednesday morning, trading at all-time highs, as investors rejoice over the Federal Reserve's apparent faith in the U.S. economy.
Impax Laboratories, Clearside Biomedical and Mylan were among the biotech stock movers in premarket trading Wednesday.
Stock futures suggest Wall Street would get back to its record-breaking ways on Wednesday as chances rose of a return to normal U.S. monetary policy sooner rather than later.
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
In one scenario, we crack these levels and then come back and retest on the pullback.
Second Successful BLA Filing of the Partnership in the U.S.
Kaleo's EpiPen compeitor the Auvi-Q was released today.
The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.
The most recent short interest data has been released for the 01/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
GlaxoSmithKline beat analysts' expectations for fourth-quarter sales and earnings Wednesday but warned of a significant hit this year from anticipated generic competition to its Advair asthma treatment.
Mylan settled a pay-for-delay lawsuit over its narcolepsy drug, but its share prices are falling.
Prices look set to test key resistance, and this time should see a breakout to the upside.